Table 2.
Group C (n=6) | Group IR (n=6) | Group IR-A (n=6) | Group IR-I (n=6) | P-value** | |
---|---|---|---|---|---|
Interstitial enlargement and congestion | 1.00±0.00 | 1.83±0.40 | 1.33±0.21 | 1.33±0.33 | 0.247 |
PMNL infiltration | 1.00±0.00* | 2.00±0.00 | 1.50±0.22* | 1.33±0.21* | 0.002 |
Alveolar edema, hemorrhage | 0.00±0.00* | 0.50±0.22 | 0.00±0.00* | 0.00±0.00* | 0.010 |
Intravascular thrombosis | 0.00±0.00 | 0.00±0.00 | 0.00±0.00 | 0.00±0.00 | – |
Pulmonary partial destruction, consolidation | 0.67±0.21* | 1.67±0.33 | 0.17±0.17* | 0.17±0.17* | <0.0001 |
Notes:
Significance level with Kruskal–Wallis test, P<0.05.
P<0.05 compared with Group IR. Group C is the Control Group, Group IR is the Ischemia Reperfusion Group, Group IR-A is the Ischemia Reperfusion Group treated with Alprostadil, Group IR-I is the Ischemia Reperfusion Group Treated with Iloprost.
Abbreviation: PMNL, polymorphonuclear leukocyte.